Cancer (malignant tumor) is one of the main causes of premature death worldwide. With the global population growth and life expectancy extension, the incidence rate of cancer will further increase. It is expected that by 2040, the burden of cancer will increase by 50%. The number of new cancer cases worldwide will reach nearly 30 million. Although there are currently some methods for treating tumors, there are still numerous unmet needs.

Baiyu Pharmaceutical actively responds to this challenge, focusing on research related to tumor radiotherapy targeted therapy, which can precisely target tumor cells and minimize damage to normal tissues, and immune anti-tumor therapy, that activates the body's immune system to fight cancer cells. Currently, two clinical studies are underway, one focusing on the combination of radiotherapy and targeted therapy for a specific type of cancer, and the other exploring the efficacy of immune checkpoint inhibitors in immune anti-tumor therapy, committed to providing more accurate tumor treatment plans for patients to save more lives.

Autoimmune diseases are a type of disease caused by the immune system attacking normal tissues and cells in the body, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, etc. For example, rheumatoid arthritis causes joint pain, swelling, and stiffness, which can significantly affect a patient's daily activities. About 5% -9% of the global population suffers from various types of autoimmune diseases, ranking it as the third largest chronic disease after cancer and cardiovascular disease. Most patients require long-term or even lifelong medication, which can affect their quality of life in mild cases and endanger their lives in severe cases.

Baiyu Pharmaceutical utilizes advanced professional knowledge and profound research and development capabilities to develop drug solutions that target specific immune pathways or use novel drug delivery systems to improve efficacy and safety. We will make every effort in pursuing scientific innovation, helping patients overcome the limitations of autoimmune diseases in their lives, and allowing patients to fully embrace a better life.

The age composition of the world's population is undergoing significant changes. According to 2019 United Nations data, the elderly population in the world has surpassed children under the age of 5 for the first time. However, the lifespan that people can live a healthy life has not increased synchronously with the increase of life expectancy. In fact, aging is the main risk factor for diseases like cancer, cardiovascular disease, and dementia.

Numerous studies have shown that anti-aging drugs can delay aging and prolong lifespan. They can also improve the quality of life and health. There are several types of anti-aging drugs, including small molecule drugs that clear aging cells, drugs that increase autophagy and reduce age-related inflammation, drugs that regulate energy metabolism, drugs targeting aging causing genes with abnormal expression, and natural products. Small molecule drugs that clear aging cells work by removing damaged or senescent cells from the body. Drugs that increase autophagy help the body's cells recycle and remove waste materials. Drugs that regulate energy metabolism can optimize the body's energy production and consumption. Drugs targeting aging causing genes with abnormal expression aim to correct genetic abnormalities that contribute to aging. Natural products offer a more holistic approach to anti-aging.

Baiyu Pharmaceutical will actively explore innovative research and development directions, such as combining multiple drug mechanisms to develop more effective anti-aging drug treatment plans. By enhancing physical function, improving cognition, and reversing aging phenotypes, it aims to help the elderly population in China and even globally extend their quality of life.